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Abstract: Spinal metastases are common in patients with cancer. As cancer treatments improve and these 
patients live longer, the number who present with metastatic spine disease will increase. Treatment strategies 
for these patients continues to evolve. In particular, since the prospective randomized controlled study in 
2005 by Patchell et al. showed increased survival with decompressive surgical treatment of spinal metastases, 
there is a growing body of literature focusing on surgical management and complications of surgery for 
this disease. Surgery is often one component of a multimodal treatment approach with chemotherapy and 
radiation, which makes it difficult to parse the benefits of each individual treatment in outcome studies. 
Additionally, there has been more recent emphasis placed on patient-reported outcomes (PRO) after 
treatment for metastatic spine disease. In this review, we summarize treatments of metastatic spinal disease, 
possible perioperative complications, and validated tools used to assess outcomes for these patients.
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Introduction
The spine is a common location of metastasis for many 
types of cancer. Some studies have estimated that over 
30% of cancer patients will develop metastatic spine 
disease (1,2). Moreover, as treatments of primary cancers 
continue to improve, and as cancer patients consequently 
live longer, the number of patients with spinal metastases 
will increase. These tumors can have debilitating effects on 
quality of life and yield complex neurological sequelae as 
a result of spinal cord compression. The management of 
spinal metastases continues to evolve, with an expanding 
importance of surgical management of these patients. 
This shift in treatment paradigms was spurred by Patchell 
et al. (3), who demonstrated increased survival with surgery 
in a landmark randomized controlled trial comparing 
surgical decompression and radiation vs. radiation alone 
for compressive spinal metastases. A bourgeoning body 
of literature on outcomes and complications of surgery 
for spinal metastases has followed. Surgery is often one 
component of a multimodal approach to spinal metastases, 
often coupled with chemotherapy and radiation. This makes 
it more challenging for outcomes studies to determine the 
true benefit of individual treatments. There is also a growing 
body of literature attempting to discern the most effective 
means by which to assess patient-reported outcomes (PRO) 
after surgery. This review will summarize recent data 
on treatment of spinal metastatic disease, complications 
resulting from surgery, and the evolution of tools used to 
assess patient reported outcomes in these patients.
Treatment of spinal metastases
To understand treatment of spinal metastases, one must 
understand the advantages and limitations of medical 
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management, radiotherapy, and surgical treatment. In 
practice, these modalities are most often used together 
rather than in isolation. 
Medical management
Chemotherapy is usually employed to gain long-term 
control of spinal metastases. It is less often used as 
monotherapy unless metastases arise from exceedingly 
chemosensitive tumors such as lymphoma, seminoma, or 
neuroblastoma. More frequently, chemotherapy is used as 
adjuvant therapy with radiotherapy (RT) or with surgery plus 
RT. The particular chemotherapeutic agent used depends 
on histology and other tumor-specific characteristics (4-6).
Corticosteroids are also a mainstay of treatment of spinal 
metastases and are thought to help alleviate vasogenic edema 
and decrease inflammation, which is especially beneficial 
in metastases producing spinal cord compression (7). 
Moreover, steroids may have a direct cytotoxic effect 
on certain hematological malignancies (myeloma and 
lymphoma) and, at times, breast cancer (5,6). Exact 
guidelines for using steroids for spinal metastases have not 
been established; dosing is generally decided on an ad hoc 
basis. Past trials have advocated both for using the minimal 
dose of steroids possible as well as treating with high-dose 
steroids (particularly when treatment also involves RT) (5,7). 
Transient improvements in ambulation may be seen after 
initiating steroids and some patients may remain on steroids 
long-term to reduce pain (6,7).
Radiotherapy
Traditionally, RT was the predominant treatment modality 
for spinal metastases. Even today, with mounting evidence 
supporting the importance of surgical intervention as part 
of management, RT remains a crucial component of the 
overall treatment algorithm. The primary goal of RT is 
generally to reduce pain from metastases, though it can 
also be used to achieve local control to treat or prevent 
neurological sequelae from spinal cord compression (6,8). 
RT can be administered via conventional external beam 
radiation therapy (EBRT), stereotactic body radiation 
therapy (SBRT), or spine-specific stereotactic radiosurgery 
(SRS), depending on the patient’s treatment goals or other 
patient-specific factors (4,5,8). 
EBRT, the most common form of RT, is regularly 
the first line of treatment for spinal metastases. A single 
standard-of-care radiation dose has not been definitively 
established and is often dependent on the radiosensitivity 
of the tumor subtype. The most common regimens are 
8 Gy in a single fraction, 20 Gy in 5 fractions, and 30 Gy in 
10 fractions (8). Past trials examining the efficacy of higher-
dose multiple-fraction RT vs. lower-dose single-fraction RT 
have found mixed results. In a meta-analysis of 25 RT trials 
for bone metastases, Chow et al. (9) found no significant 
differences in pain relief rates between 8 Gy single-fraction 
and 20–30 Gy multiple-fraction RT regimens, though the 
retreatment rate was higher in the single-fraction group. 
Higher-dose multiple-fraction RT may produce superior 
results compared to lower-dose single-fraction RT, but this 
is also dependent on tumor histology (4,8). EBRT at a dose 
of 30 Gy in 10 fractions may achieve effective local control 
in certain metastases such as lymphoma, myeloma, breast 
cancer, prostate cancer, and germinoma (8). Such a protocol 
is thus commonly used for spine metastases. However, for 
radioresistant tumors such as sarcomas, colorectal cancer, 
malignant melanoma, and renal cell carcinoma, local control 
rates fail to reach 50% at this dosage (8). For these tumors 
there is increasing data that larger radiation doses, for 
instance 40 Gy over 20 fractions, may yield better control 
rates (4,8).
SBRT and SRS are more novel, targeted RT modalities 
that can focus a greater amount of radiation on a tumor 
while reducing radiation toxicity to the surrounding tissues 
(10,11). SBRT may be given in 2–5 fractions; SRS is often 
given as only a single dose. The ideal radiation dose and 
schedule for SBRT and SRS are less universally agreed upon 
compared to EBRT. Nevertheless, because these forms 
of RT can deliver a more concentrated dose of radiation, 
quantities up to three times higher than with EBRT may 
be given, which results in improved local control (4,10,11). 
Indeed, when compared to EBRT, this higher achievable 
radiation dose makes this modality of RT less dependent on 
the radiosensitivity/radioresistance of a tumor in order to 
alleviate disease burden (4). When to use SBRT or SRS in 
lieu of EBRT as first-line treatment is an area under active 
investigation. Also, under investigation is the role of heavy 
particle radiotherapy such as proton beam or carbon ion 
therapy for spinal metastases. Considerably more research 
is needed on this topic, but the proposed benefits of such 
radiotherapy would be akin to SBRT or SRS (higher 
radiation doses with less damage to surrounding tissues) (12).
Surgery
Surgery is now recognized as an integral component of the 
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treatment of spinal metastases. It may be used for several 
reasons: to address neurologic symptoms of spinal cord 
compression, to stabilize spinal instability, to reduce pain, 
to remove epidural tumor before SBRT or SRS, and to 
provide a histological tumor diagnosis (see Figure 1 for 
example) (4,6). 
A new emphasis on the importance of surgery for 
spinal metastases has developed over the past 10–15 years 
following the seminal 2005 study by Patchell et al. (3) that 
provided prospective, randomized controlled trial evidence 
supporting the use of decompressive surgery for such 
patients. In this trial, patients with spinal metastases were 
randomized to receive either surgery (n=50) followed by 
RT or RT alone (n=51). A statistically significant difference 
in mean survival was seen between the two groups, with 
patients receiving surgery followed by RT surviving 
126 days as compared to 100 days in the group that received 
RT alone (P=0.033). Additionally, neurological functioning, 
as determined by ASIA and Frankel scales, was sustained 
for 566 days on average in the surgery plus RT group vs. 
Figure 1 Preoperative full length and thoracic lateral plain films (A), sagittal T2 MRI (B, left), axial T2 MRI (B, right upper), and axial 
CT (B, right lower), and postoperative AP and lateral full-length plain films (C) of a 47-year-old female with metastatic breast cancer. The 
patient has a T10 compression fracture with cord compression resulting in mid back pain and thoracic myelopathy. Surgery was performed 
to decompress the spinal cord and provide stability to decrease pain.
A B
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72 days in the group receiving RT alone (P=0.001 for 
ASIA and P=0.0006 for Frankel). The ability to walk was 
significantly prolonged in patients who received surgery 
and RT instead of only RT (122 vs. 13 days; P=0.003), 
and more patients who were unable to ambulate at the 
study’s onset regained the ability to walk after surgery and 
RT compared to solely RT (62% and 19%, respectively; 
P=0.01). Continence was significantly prolonged (P=0.016) 
and significantly smaller doses of corticosteroids (P=0.0093) 
and opioid analgesics (P=0.002) were required in the group 
that received surgery. Surgery did not lead to prolonged 
hospitalization. Despite critiques that the trial excluded 
highly radiosensitive tumors and had a low enrollment rate, 
it provided convincing evidence of the benefits conferred by 
surgery. Indeed, because of the notably better outcomes in 
the surgery group, this study was halted early. 
Following Patchell et al. there has been a bourgeoning 
body of literature that illustrates similar benefits of surgery 
(6,13-22). A study by Ibrahim et al. (18) helped to support 
the results of the Patchell trial. This prospective study 
examined outcomes for 223 patients who underwent surgery 
with or without radiotherapy and/or chemotherapy for 
spinal metastases of epithelial origin. After surgery, median 
survival was 11.7 months, 71% of patients had improved 
pain, 53% regained or maintained ambulation, and 39% 
regained urinary continence. As the authors noted, these 
results compared favorably to the most positive reported 
outcomes for patients treated by solely RT (23). Falicov 
et al. (16), in a study of 85 patients who underwent surgery 
for spinal metastases, concluded that surgery resulted in 
statistically significantly reduced levels of pain (P<0.00001) 
and improvements in patient-reported quality of life at 
6 weeks (P=0.017), 3 months (P=0.039), and 6 months 
(P=0.013), with low complication rates. Thomas et al. (24) 
used the data from the Patchell trial and examined the cost-
effectiveness of surgery and RT compared to RT alone 
for spinal metastases. These researchers determined that 
surgery plus RT was cost-effective with respect to both the 
cost per additional day of ambulation and the cost per life-
year gained. 
Though surgery is now a key aspect of management 
for spinal metastases, surgery alone is almost invariably 
palliative. The choice of surgery should depend on a 
patient’s goals for treatment, the number and location of 
metastases, and other individual patient characteristics 
(4-6,22). Surgery should be performed as soon as possible 
after diagnosis of metastases for optimal outcomes (25). 
Because its benefits are not immediate, surgery is most 
effective when a patient’s life expectancy is longer than 
8–12 weeks and when the risks are outweighed by the 
potential improvements (6,26). At times, aggressive 
resection of metastases via en bloc resection has been 
shown to achieve high local control rates, but this does not 
completely preclude future metastases and is most effective 
for patients with a single metastasis (4-6,21). Moreover, 
many patients have spinal instability, poor neurological 
status, or goals of care that obviate en bloc resection, and 
these procedures are accompanied by relatively high 
morbidity (6,21). Debulking (when the tumor is resected 
in portions) or palliative (when the goal is primarily to 
reduce spinal cord compression) approaches may be used if 
en bloc resection is not possible (5,19,27). Stabilization can 
be performed to address spinal instability with or without 
accompanying decompression. Instrumentation is often 
depended on for long term stabilization, as there is often a 
high probability that the spine will not fuse properly around 
sites of metastases due to large gaps in bony structures, 
local bone destruction by the tumor, and radiotherapy 
and/or systemic therapy, which can interfere with the 
fusion process (see Figure 2 for example). We advocate for 
the use of bone graft or bone graft substitute to promote 
fusion, because fusion is possible in these patients despite 
unfavorable circumstances.
Cement augmentation of vertebral bodies has also 
demonstrated efficacy, especially in patients with tumors in 
the anterior section of the spine (4-6,19). The use of cement 
augmentation through fenestrated screws is a newer trend 
that may prove similarly useful for mechanical strengthening 
of spinal constructs in bone that has been pathologically 
weakened by tumor (28,29). Spinal decompression may be 
via anterior or posterior approaches, with no consensus in 
the literature as to which is the superior approach (13,30). 
Recently, minimally invasive spine surgery has been shown 
to be a safe and effective technique for decompression and 
stabilization of the spine that may yield improved functional 
outcomes and quality of life (31-33). 
Since surgery alone likely does not resolve a sufficient 
amount of tumor burden, it is often used in conjunction 
with pre- and/or postoperative RT. Research suggests that 
the timing between surgery and RT should be 1–2 weeks 
both before and after surgery in order to avoid spurring 
postsurgical complications (34,35). 
Separation surgery is a newer approach by which spinal 
decompression is performed to create an advantageous 
opening to the tumor through which SBRT or SRS can 
deliver a more targeted dose of radiation (8,30,36). There 
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are a number of approaches that can be used for separation 
surgery, but the transpedicular approach appears to be safe 
and the most versatile method for a wide range of tumor 
locations (4). The indications for postoperative RT are still 
the subject of some debate (37). A prior cost-utility analysis 
by Furlan et al. (38) concluded that while surgery plus 
RT was more expensive, this combination also generated 
superior outcomes to RT alone. 
Kyphoplasty or vertebroplasty are more conservative 
treatments that may be used primarily to manage pain 
after compression fractures. These treatments can also 
help provide spine stability in the setting of lytic metastatic 
disease, particularly in patients with anterior spine 
instability and those undergoing RT (19).
Complications
Surgery for metastatic spine disease is subject to all 
the risks of non-oncologic spine surgery, with the 
added complicating factors of radiation, chemotherapy, 
Figure 2 Preoperative lateral plan film and T1 MRI (A), lateral and coronal CT scan (B), and postoperative AP and lateral plain films of 
a 66-year-old male with metastatic bladder cancer who presented with difficulty breathing and progressive C5 level weakness after 3 days 
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coagulopathies, and medical fragility of oncology patients. 
A thorough understanding of the risks vs. potential benefits 
is required to make informed decisions about whether an 
operation is worth pursuing. A recent study of 647 patients 
undergoing a primary surgery for cervical, thoracic, or 
lumbar metastatic spine disease estimated a 32% 30-day 
complication rate after surgery, with 18% undergoing at 
least one reoperation (39). This is not insignificant, as these 
complications can potentially decrease quality of life after 
surgery, which is generally the primary goal. Experiencing 
a complication was also associated with decreased survival. 
Factors associated with developing complications were low 
albumin, additional comorbidities, pathologic fractures, 
three or more spine levels operated upon, or a combined 
surgical approach. These risk factors highlight the medical 
and surgical complexity of these patients that is often not 
modifiable.
Instrumentation failure is a known complication after 
surgery for spinal metastases. Abnormal biology in the area 
where fusion is desired may disrupt bone formation, and 
this can be further compounded by systemic chemotherapy 
or local radiation. Therefore, a majority of the forces may 
continue to be borne by instrumentation when fusion is not 
possible, due to either bone removal in a decompressive 
surgery or bone destruction by tumor. Instrumentation 
failure may become a more common complication as survival 
increases in these patients. A recent single center cohort 
study of 159 patients found a 1.9% rate of instrumentation 
failure requiring reoperation after surgery for metastatic 
spine disease, with previous radiation to the area being a 
significant risk (40). The mean survival after surgery of those 
without instrumentation failure was 17 months, so many 
patients succumbed to their disease before instrumentation 
may have failed. Another study of 318 patients at a single 
center reported a 2.8% instrumentation failure rate 
requiring reoperation, with chest wall resection and greater 
than six spinal levels of surgery being risk factors (41), and 
a third study of 289 patients had a 3.1% reoperation rate 
for instrumentation failure (42). Along with these factors, 
a systematic review found that positive sagittal balance 
and preoperative radiation may contribute to implant 
failures (43). Kumar et al. proposed a classification of these 
implant failures, dividing failures into early (<3 months) 
or late (>3 months), and then further subdividing based 
on whether the failure is symptomatic (44). The authors 
did not propose a full treatment algorithm; rather, they 
noted that there are a significant number of asymptomatic 
patients that may not need revision despite radiographic 
failure. They emphasized that surgery should be avoided 
with these patients to avoid further morbidity. This has 
been factored into the studies reported here, which only 
report instrumentation failure requiring reoperation and not 
asymptomatic failure.
Just as disruption of biology may affect fusion, it may also 
affect wound healing and increase risk for infection. One 
study from 2011 reported a very high rate of surgical site 
infection (SSI) after spine surgery for metastatic disease, up 
to 8.4% (45). Studies since then have found much lower SSI 
rates. In a cohort of 159 patients at a single center, 22 of 159 
patients required reoperation due to wound dehiscence (6) 
or wound infection (16,46). Thromboembolic events and 
increasing number of levels were associated with reoperation 
in a multivariate model. Quraishi et al. found that infection 
was the most common reason for reoperation on 384 
patients who underwent spine surgery for metastatic disease 
(42% of second procedures), with an overall infection 
rate of 4.5% (9/234) (42). A recent systematic review 
attempted to find risk factors for wound complications and 
preventative factors (43). After reviewing 40 articles, there 
was a low level of evidence that preoperative radiation, 
preoperative neurological deficit, revision surgery, and 
posterior approaches contribute to wound complications. 
Plastic surgery soft tissue reconstruction, intrawound 
vancomycin powder, and percutaneous pedicle screw 
instrumentation may be protective. As minimally invasive 
surgery and separation surgery techniques evolve, there may 
be the potential to further decrease wound complications 
through the use of tissue sparing techniques. The current 
literature does not contain a sufficient number of high-
quality studies to support that hypothesis at this time (47).
Cost and value are becoming increasingly important 
factors for measuring outcomes of medical care. To that 
end, unplanned readmissions is an important metric that 
can have a significant impact on cost as well as serve as an 
indicator of morbidity associated with these procedures. 
Two recent single center studies of 164 and 159 patients 
looked at readmissions after surgery for metastatic spinal 
disease (48,49). Thirty-day readmission rates were from 
13.8–16.8% and 1-year readmissions were 37.8–47.2%, with 
approximately 33% due to recurrent disease, 25% due to 
infection, and 37–43% as a result of medical complications. 
Prior hospitalization of 15 days and lung metastases were 
independent risk factors for readmission. Another single 
center study of 181 patients with both primary and metastatic 
tumors reported an overall perioperative complication 
rate or 21.0% with 11.9% 90-day readmissions, costing 
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approximately $20,000 each (50). 
Other factors that may affect complication rates 
include patient age and location of spinal metastases. In a 
multicenter study of 1,266 patients by the Global Spine 
Tumor Study group, increased age was associated with 
increased rates of complications (33.3% >80 years old, 
23.9% 70–80 years old, and 17.9% <70 years old), with 
longer life expectancy in the youngest group and less 
neurologic recovery in the older group (51). From the 
American College of Surgeons National Surgical Quality 
Improvement Program database, cervical location of 
metastases are associated with highest risk of pulmonary 
complications and thoracic tumors are associated with 
highest risk of blood transfusion, whereas lumbosacral 
tumors have lower odds of perioperative mortality, 
pulmonary complications, and sepsis (52). 
Blood transfusion is also associated with complications. 
In a single center study, the odds ratio of developing post-
operative complications was 2.27 times higher in those 
who received a transfusion than in those who did not, with 
an increase in odds ratio of 1.24 per unit transfused (53). 
Transfusion is not associated with increased overall survival 
or disease-free survival (54). One method for decreasing 
transfusion rate is intraoperative cell salvage (IOCS) with 
a leukocyte depletion filter to remove malignant cells (55). 
IOCS can replace approximately 50% of the red blood cells 
lost during surgery while removing tumor cells. Recent 
advances in selective filtration have been demonstrated to 
be safe in oncologic surgery in gynecology, hepatobiliary 
surgery, gastrointestinal surgery, and urology, but there is 
a paucity of evidence in spinal metastatic disease. There is 
currently one study that reported lower blood transfusion 
rates and shorter lengths of stay with use of this technology 
in surgery for spinal metastases, with no difference in 
survival or complication rates (56). It will likely take more 
in depth and larger studies to establish this as a safe and 
effective technique in musculoskeletal tumor surgery.
Outcomes for spinal metastases
Survival and prognostic factors
Mean survival for spinal metastases is dependent on tumor 
histology and, depending on the study cited, may range 
from 51 months for myeloma to 26 months for thyroid 
cancer to less than 6 months for lung, stomach, esophagus, 
or pancreatic cancer (57,58). A number of studies (57-63) 
have attempted to identify prognosticators or use scoring 
systems to predict post-treatment survival in these patients. 
A systematic review and meta-analysis by Luksanapruksa 
et al. (64) identified seventeen prognosticators of poor 
outcomes across 43 studies, including factors such as 
age >65 years old, multiple metastases (bone or visceral), 
≥3 involved vertebrae, non-ambulatory status before 
treatment, KPS <70, male gender, and increasing time 
from cancer diagnosis to surgery. Some commonly cited 
predictive systems are the Tomita, van der Linden, Bauer, 
modified Bauer, and revised Tokuhashi (58). These systems 
all incorporate various combinations of primary tumor 
characteristics, sites and number of metastases, neurological 
functioning metrics, or performance scores. The Bauer 
score and modified Bauer score were considered the 
most predictive scales (58,59), although recent studies 
(60,61) posit that a modified Bauer score that incorporates 
ambulatory status and serum albumin may be a significantly 
more accurate predictor than the modified Bauer scale 
alone. Regardless, treatment decisions, including whether 
or not to perform surgery, should not be guided solely by a 
prognostic model—they should be grounded in a patient’s 
symptoms, neurological compromise, and overall fitness. 
Quality of life
Until relatively recently, most outcome measures for 
treatment of spinal metastases focused on survival, 
recurrence, complications, or measures of function or 
neurological status (65); less attention was paid to how 
patients characterized their own health. Consequently, there 
has been a push towards self-reported assessments of patients’ 
health and quality of life. Most of these data are accrued by 
assessing PRO via validated questionnaires (58). Some of these 
questionnaires are specific for spinal metastatic disease, 
while others may be designed more for patients with cancer 
or neck/back pain of any kind. Regarding more commonly 
used measures of quality of life for spinal metastases, the 
EuroQol 5-Dimensions (EQ-5D) is designed to elicit 
responses about patients’ health status in general. The 
Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) 
also has been used, though this is a lengthy questionnaire 
and is not specific for spinal metastases. Because spinal 
metastases frequently cause neck and back pain, the Neck 
Disability Index (NDI) and the Oswestry Disability Index 
(ODI) have been used to assess quality of life, but these 
scales are also not specific for this patient population. To 
address these shortcomings, in 2010 the Spine Oncology 
Study Group created the Spine Oncology Study Group 
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Outcome Quest ionnaire (SOSG-OQ),  which was 
subsequently validated in 2015 specifically for patients with 
spinal metastases (65,66). The SOSG-OQ has since been 
lauded as more useful than older tools for assessing patient-
reported quality of life (67).
PROMIS
The ideal PRO measuring tool is a scale that adapts 
to a patient’s responses in order to generate the most 
individually-crafted questionnaire. To this end, Computer 
Adaptive Testing (CAT) can offer a dynamic system that can 
generate specific questions based on patients’ prior answers 
to provide the most reliable and complete assessment 
(68-70). This kind of questionnaire is able to include 
metrics and incorporate patient characteristics that may not 
be captured by other PRO measurements such as the EQ-
5D or the SOSG-OQ (70). 
In 2004, the National Institutes of Health created the 
Patient-Reported Outcomes Measurement Information 
System (PROMIS) in order to improve patient self-
reporting of symptoms, functioning, and quality of life (68). 
PROMIS utilizes Item Response Theory (IRT), which is 
a testing theory that ensures that each individual question 
is validated for application to the objective of the test as 
a whole (68). Moreover, PROMIS may be administered 
by computer to achieve the benefits of CAT. In sum, this 
ensures that PROMIS is a flexible and comprehensive 
assessment of PRO that can achieve greater accuracy while 
measuring a wide range of desired outcomes. PROMIS can 
also give T-scores for a patient’s reported outcomes, with a 
standardized mean score of 50 and a standard deviation of 
10, which makes the output easier to understand and place 
into context alongside other patients (68,69). 
PROMIS has been studied in patients with non-cancer 
spine conditions, where it has been shown to take less time 
to complete, have lower ceiling and floor effects, and to be 
just as valid when compared to more traditional, “static” 
spine PRO assessment scales (71). Few studies have used 
PROMIS specifically for metastatic spine disease. When the 
SOSG-OQ first was released in 2010, it was recommended 
by the SOSG for metastatic spine disease given its superior 
content capacity to measure disease burden (65) compared 
to other scales at that time. However, since then, PROMIS 
has often been lauded as the measurement tool of choice 
for PRO with spine metastases. Studies by Paulino Pereira 
et al. (67) and Bernstein et al. (72) compared PROMIS to 
other PRO questionnaires (ODI, NDI, EQ-5D, or SOSG-
OQ) to assess pain and physical function for 100 and 
51 patients, respectively, with spinal tumors. Both studies 
concluded that PROMIS was the superior measurement 
tool for most patient subgroups when compared to 
nearly every other PRO instrument. The one exception 
was that SOSG-OQ may be superior to PROMIS for 
measuring quality of life (67). Findings from Colman 
et al. (73), concluded that PROMIS was a superior and 
more responsive tool compared to EQ-5D, NDI, and ODI 
for assessing quality of life for 27 patients who underwent 
surgery and eight patients who underwent RT for spine 
tumors. Another study by van Wulfften Palthe et al. (74) 
compared PROMIS to number of older PRO measuring 
systems for patients with sacral spinal tumors, with the 
researchers recommending that PROMIS surveys be used 
to assess quality of life in areas such mental health, physical 
health, pain, gastrointestinal symptoms, sexual function, 
and social health. Given the comprehensiveness, efficiency, 
adaptability, and validity of PROMIS, the literature appears 
to be trending towards this becoming the gold standard for 
assessing PRO for metastatic spine disease. For measuring 
quality of life, both PROMIS and the SOSG-OQ may be 
used reliably. 
Conclusions
Spinal metastases are a complex but common manifestation 
of primary cancers throughout the body. The management 
of these patients should incorporate individual patient and 
tumor characteristics, and most likely should involve a 
multifaceted approach involving radiation, chemotherapy, 
and surgery. Surgery, even despite its risks and complications, 
should be used whenever possible for these patients, as it 
can provide the longest added survival and superior relief of 
symptoms. There are many different prognostic variable or 
models that may predict some aspects of patient outcomes. 
With respect to measuring PRO after surgery, PROMIS 
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